Williamson L M
Division of Transfusion Medicine, University of Cambridge, UK.
Blood Coagul Fibrinolysis. 1992 Oct;3(5):643-6. doi: 10.1097/00001721-199210000-00020.
Several clinical complications of platelet transfusions relate to contaminating donor leucocytes, and a number of strategies have been devised to leucodeplete platelet products before transfusion. Both alloimmunization to class I human leucocyte antigens (HLA), which causes febrile transfusion reactions and refractoriness to transfused platelets, and transmission of cytomegalovirus have been shown to be reduced by 3-log10 leucodepletion by filtration. Lesser degree of leucodepletion, e.g. by platelet preparation from buffy coats, will control febrile transfusion reactions, but will not reliably prevent other complications. The clinical implications and cost-effectiveness of different strategies of platelet production remain a matter of debate.
血小板输注的几种临床并发症与污染的供体白细胞有关,并且已经设计了许多策略在输血前对血小板制品进行白细胞去除。通过过滤进行3-log10的白细胞去除已显示可减少对I类人类白细胞抗原(HLA)的同种免疫(这会导致发热性输血反应和对输注血小板的不应性)以及巨细胞病毒的传播。较低程度的白细胞去除,例如通过从 Buffy 层制备血小板,将控制发热性输血反应,但不能可靠地预防其他并发症。不同血小板生产策略的临床意义和成本效益仍是一个有争议的问题。